SM
ATOS icon

Sabby Management’s Atossa Therapeutics ATOS Stock Holding History

Sabby Management’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1
Closed -$1.37K – 29
2024
Q3 		$1.37K Buy
+1
New +$20 ﹤0.01% 42
2022
Q4 		– Sell
-313
Closed -$391K – 110
2022
Q3 		$391K Sell
313
-431
-58% -$6.26K 0.49% 44
2022
Q2 		$1.22M Sell
744
-19
-2% -$299 0.83% 23
2022
Q1 		$1.43M Sell
763
-62
-8% -$1.26K 0.21% 31
2021
Q4 		$1.98M Sell
825
-223
-21% -$8.16K 0.29% 54
2021
Q3 		$5.13M Sell
1,048
-648
-38% -$37.7K 0.69% 15
2021
Q2 		$16.1M Buy
1,696
+851
+101% +$45.1K 2.27% 7
2021
Q1 		$2.67M Buy
+845
New +$30.9K 0.52% 37

Other funds holding ATOS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Sabby Management's ATOS Position: Q2 2023 in Review

Sabby Management sold out of Atossa Therapeutics (ATOS) in Q2 2023, closing a stake of 4,381 shares — an estimated $47.6K sold.

Sabby Management first reported a position in ATOS in Q2 2017 and held it in 11 quarters. The position peaked at $6.61M in Q2 2021. 52 funds tracked by Wall St. Rank hold ATOS as of Q2 2023.

  • Sabby Management reported no remaining Atossa Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Sabby Management sold 4,381 Atossa Therapeutics shares in Q2 2023, an estimated $47.6K.
  • Sabby Management first reported a position in Atossa Therapeutics in Q2 2017 and held it in 11 quarters.
  • Sabby Management's Atossa Therapeutics position peaked at $6.61M in Q2 2021.
  • 52 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q2 2023.

Based on Sabby Management's 13F filing for Q2 2023, filed 14 Aug 2023.